Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Investing Activities: 2011-2024

Historic Cash from Investing Activities for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to -$96.4 million.

  • Iovance Biotherapeutics' Cash from Investing Activities rose 134.86% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.4 million, marking a year-over-year increase of 136.49%. This contributed to the annual value of -$96.4 million for FY2024, which is 37.90% up from last year.
  • Iovance Biotherapeutics' Cash from Investing Activities amounted to -$96.4 million in FY2024, which was up 37.90% from -$155.2 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Cash from Investing Activities ranged from a high of $256.5 million in FY2022 and a low of -$317.9 million during FY2020.
  • In the last 3 years, Iovance Biotherapeutics' Cash from Investing Activities had a median value of -$96.4 million in 2024 and averaged $1.6 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Cash from Investing Activities tumbled by 453.07% in 2020 and then skyrocketed by 194,184.09% in 2022.
  • Yearly analysis of 5 years shows Iovance Biotherapeutics' Cash from Investing Activities stood at -$317.9 million in 2020, then surged by 100.04% to $132,000 in 2021, then surged by 194,184.09% to $256.5 million in 2022, then plummeted by 160.53% to -$155.2 million in 2023, then skyrocketed by 37.90% to -$96.4 million in 2024.